Table 1.
Correlation of clinicopathological features and expression of CagA and NFATc1 with tumor response to HPE therapy in gastric MALT lymphoma
| Lymphomas response to HPE | ||||
|---|---|---|---|---|
| Clinicopathological characteristics |
Total number (n = 91) |
HPE-responsive (n = 59) |
HPE-irresponsive (n = 32) |
p* |
| Age (median, range, years) | 56.0 (20–86) | 57.0 (30–86) | 53.5 (20–79) | 0.326# |
| Sex, men/women | 38/53 | 23/36 | 15/17 | 0.466§ |
| Endoscopic features, n (%) | 0.084‡ | |||
|
Gastritis-like or multiple erosion on infiltrative mucosa |
35 (39%) | 27 (46%) | 8 (25%) | |
| Ulceration or ulcerated mass | 40 (44%) | 23 (39%) | 17 (53%) | |
| Erosions on giant nodular folds | 16 (17%) | 9 (15%) | 7 (22%) | |
| Location of lymphoma(s), n (%) | 0.073§ | |||
| Proximala or ≥ 2 components | 29 (32%) | 15 (25%) | 14 (44%) | |
| Distalb | 62 (68%) | 44 (75%) | 18 (56%) | |
| Stage | 0.400§ | |||
| IE | 70 (77%) | 47 (80%) | 23 (72%) | |
| IIE1 | 21 (23%) | 12 (20%) | 9 (28%) | |
| Depth of gastric wall involvement, n (%)¶ | 0.055§ | |||
| Submucosa or above | 52/86 (61%) | 38/56 (68%) | 14/30 (47%) | |
| Muscularis propria or beyond | 34/86 (39%) | 18/56 (32%) | 16/30 (53%) | |
| CagA expression | < 0.001§ | |||
| Positive | 54 (59%) | 47 (80%) | 7 (22%) | |
| Negative | 37 (41%) | 12 (20%) | 25 (78%) | |
| Nuclear localization of NFATc1 | < 0.001§ | |||
| Presence | 51 (56%) | 43 (73%) | 8 (25%) | |
| Absence | 40 (44%) | 16 (27%) | 24 (75%) | |
| T(11;18)(q21;q21)/BIRC3-MALT1 | < 0.001§ | |||
| Positive | 10 (11%) | 0 (0%) | 10 (31%) | |
| Negative | 81 (89%) | 59 (100%) | 22 (69%) | |
p*: comparison of discrete variables between HPE-responsive cases and HPE-irresponsive cases
#p values (two-sided) were calculated using the Student’s t-test
§p values (two-sided) were calculated using Chi-square test or Fisher’s exact test
‡p values (two-sided) were calculated using one-way analysis of variance
Proximala: Middle body, upper body, fundus, or cardia. Distalb: Antrum, angle, or lower body
Gastric wall involvement was evaluated by endoscopic ultrasonography in 86 patients. HPE Helicobacter pylori eradication therapy, MALT mucosa-associated lymphoid tissue